香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025 年1 2 月3 1 日 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 參與設立之私募股權投資基金進展的公告》，僅供參閱。 承董事會命 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生、王可心先生及劉毅先生；本公 司之非執行董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生及楊玉成先生；以及本公司職工董事為嚴佳女士 ...

上海复星医药（集团）股份有限公司 证券代码：600196 股票简称：复星医药 编号：临 2025-207 关于参与设立之私募股权投资基金进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、参与设立之私募股权投资基金的基本情况 2022 年 1 月 7 日，包括本公司控股子公司/企业大连复健、宁波复瀛在内的 5 方投资人签订《合伙协议》，以共同出资设立大连星未来基金。该基金募集资 金人民币 50,000 万元，专注于参股投资医疗器械、医疗科技及相关产业的初创 期、早中期创新型企业。2022 年 2 月 23 日，该基金于中基协完成私募投资基金 备案。 有关该基金募集及过往投资人变动的详情，请见本公司 2022 年 1 月 8 日、 2022 年 2 月 25 日、2024 年 10 月 18 日、2024 年 12 月 12 日、2025 年 12 月 3 日于《中国证券报》《上海证券报》《证券时报》和上海证券交易所网站 （https://www.sse.com.cn）发布的相关公告。 二、本次进展 鉴于标的基金 L ...

致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年12月31日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,50 ...

Group 1: New Drug Listings - The new National Medical Insurance Drug List will add 114 drugs, including 50 innovative drugs, increasing the total to 3,253 drugs [1] - The Commercial Health Insurance Innovative Drug List will include 19 drugs, with 5 being CAR-T therapies [1] Group 2: Local Production Strategies - Companies like Innovent Biologics are optimistic about the market entry of their drug, "Tislelizumab," which is now covered by the national insurance [2] - Fosun Pharma has adopted different production strategies for its drugs, including "raw material reserves and flexible production" for "Luwomeitini" and a dual strategy of "short-term imports and long-term localization" for "Tianapano" [3] - Marubeni Pharma has localized production for its drugs, ensuring stable supply through hospital access and dual-channel pharmacies [3] Group 3: Accessibility Enhancements - Companies are adjusting inventory, pricing, and reimbursement information for new innovative drugs in line with national negotiation policies [4] - The "dual-channel" system allows patients to access drugs through designated medical institutions and retail pharmacies, ensuring quick prescription flow [4] - National Pharmaceutical Holdings is assisting drug companies in pricing and insurance coding for newly introduced innovative drugs in Shanghai [4] Group 4: Hospital Integration and Evaluation - Hospitals are considering various factors for integrating innovative drugs, including overall insurance funding and clinical efficacy assessments [5] - Shanghai Zhongshan Hospital is adopting a principle of "as much as possible" for including new innovative drugs in their formulary [5] - Research and monitoring of adverse reactions for newly added innovative drugs are being emphasized to ensure safety and efficacy in clinical settings [5]

致：香港交易及結算所有限公司 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 公司名稱: 上海復星醫藥(集團)股份有限公司 ( 於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年12月31日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02196 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 551,940,500 | RMB | | 1 RMB | | 551,940,50 ...

Core Insights - The company reflects on a year of significant achievements in the biopharmaceutical sector, highlighting the successful clinical use of its innovative drug, Revamin, and the approval of multiple CAR-T products, showcasing its commitment to addressing rare diseases and cancer treatment gaps [3][6][33] - Club Med has seen substantial growth, with global revenue projected to increase from €1.5 billion in 2015 to €2.1 billion in 2024, and operating profit has grown over five times, indicating strong market demand for innovative travel experiences [9][40] - The company emphasizes its focus on user-centered product development in the tourism sector, aiming to enhance family vacation experiences rather than merely creating tourist attractions [6][38] Biopharmaceutical Innovations - Revamin has been officially launched for clinical use, filling a treatment void for rare tumors in China [3][7] - The company has successfully developed and received approval for multiple innovative drugs, including the first CAR-T product for gastric cancer, which has been recognized as a breakthrough therapy [6][38] - Since 2019, the company has launched a total of 12 innovative drugs, demonstrating its ongoing commitment to patient care and treatment advancements [3][33] Tourism and Leisure Sector - Club Med's performance has reached new heights, with an increasing number of families prioritizing snow vacations, supported by the ongoing development of the "Super Mediterranean" project [6][38] - The company has introduced three core product lines in the tourism sector, focusing on user needs to enhance vacation experiences [6][38] - Atlantis in Sanya has solidified its leading position in the vacation market, with annual visitor numbers reaching 1.5 million [11][43] Globalization and Market Expansion - The company has achieved over 50% of its revenue from international markets, highlighting its successful globalization strategy [16][45] - The Portuguese insurance subsidiary has seen nearly 30% of its business come from international operations, contributing to a diversified revenue stream [16][45] - The company has established strategic partnerships, such as with Fakeeh Care Group in Saudi Arabia, to expand its CAR-T technology internationally [16][46] Cultural and Community Engagement - The company has actively engaged in cultural initiatives, such as the successful summer event at Yuyuan Garden, attracting over 7.5 million visitors, with a significant portion being young people [52] - The company has been recognized for its commitment to social responsibility, being included in the S&P Global Sustainability Yearbook for the second consecutive year [54] - Ongoing support for educational and healthcare initiatives, including donations to Fudan University Affiliated Hospital, reflects the company's dedication to community welfare [57]

Overview - Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the initiation of Phase I clinical trials for its integrated diagnostic and therapeutic nuclear medicine project SRT-007, targeting PSMA-positive metastatic castration-resistant prostate cancer in mainland China [2]. Drug Information and Research Status - The SRT-007 project includes two injectable radioactive drugs: Gallium [68Ga] PSMA-0057 for diagnosis and Lutetium [177Lu] PSMA-0057 for treatment [3]. - As of November 2025, the cumulative R&D investment for SRT-007 is approximately RMB 32.19 million (unaudited), which includes licensing fees [3]. - The only approved drug targeting the same receptor globally is NOVARTIS AG's Pluvicto, which reported global sales of USD 1.392 billion in 2024 [3].

Core Viewpoint - Fosun Pharma plans to acquire controlling interest in Green Valley Pharmaceutical for over 1.4 billion yuan, focusing on the development of the Alzheimer's treatment drug, Ganluotena Capsules [1] Group 1: Acquisition Details - The acquisition will be executed through a combination of "old share transfer + subscription of new registered capital," with a total investment of 1.412 billion yuan [1] - Of the total investment, 1.269 billion yuan will be used for subscribing to new registered capital, primarily for clinical research and daily operations of Green Valley [1] - The remaining 143 million yuan will be used for acquiring old shares, indicating that over 1.2 billion yuan will directly support Green Valley's business development [1] Group 2: Product Focus - The core focus of this investment is on Ganluotena Capsules, which previously faced setbacks in international clinical trials [1] - The Phase III confirmatory clinical trial was terminated in 2022 due to multiple factors, including the COVID-19 pandemic, funding, and management issues [1] - Fosun Pharma aims to restart the international trials for this product following the acquisition [1] Group 3: Financial Impact - As of September 30, 2025, Green Valley's consolidated assets and liabilities are 806 million yuan and 795 million yuan, respectively, which have a limited impact on Fosun Pharma's overall asset and liability structure [2] - The financial impact of the acquisition is controllable, with expected manageable operating losses and capitalized costs for the confirmatory clinical research of Ganluotena Capsules [2] - Fosun Pharma has been focusing on optimizing its asset structure and cash flow, with over 2 billion yuan in signed disposal projects in the first eight months of 2025 [2] Group 4: Investor Confidence - Fosun Pharma is implementing clear growth targets and share buybacks to maintain investor confidence, aiming for nearly 20% annual growth in net profit and innovative drug revenue [2] - The company has repurchased 14.23 million A-shares for approximately 348 million yuan and 3.41 million H-shares for about 47.84 million HKD to bolster market confidence [2]

Core Viewpoint - Fosun Pharma has initiated Phase I clinical trials for its integrated diagnostic and therapeutic nuclear medicine project SRT-007 in mainland China, targeting PSMA-positive metastatic castration-resistant prostate cancer [1] Group 1: Project Details - The SRT-007 project includes two injectable radioactive drugs: Gallium [68Ga] PSMA-0057 for diagnosis and Lutetium [177Lu] PSMA-0057 for treatment [1] - The total R&D investment for SRT-007 is approximately RMB 32.19 million (unaudited), including licensing fees, expected to be accumulated by November 2025 [1] Group 2: Market Context - As of the announcement date, the only approved radioactive drug targeting the same site globally is Pluvicto by Novartis AG, which is projected to generate global sales of USD 1.392 billion in 2024 [1]

Core Viewpoint - Fosun Pharma (600196)(02196) has initiated Phase I clinical trials for its integrated nuclear medicine project SRT-007 in mainland China, targeting the diagnosis and treatment of PSMA-positive metastatic castration-resistant prostate cancer [1] Group 1 - The project SRT-007 is developed by Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., a subsidiary of Fosun Pharma [1] - The clinical trial is specifically focused on patients with PSMA-positive metastatic castration-resistant prostate cancer [1]